The stock of DBV Technologies ADR (DBVT) has gone down by -24.44% for the week, with a -27.67% drop in the past month and a -44.39% drop in the past quarter. The volatility ratio for the week is 10.61%, and the volatility levels for the past 30 days are 12.12% for DBVT. The simple moving average for the last 20 days is -28.93% for DBVT stock, with a simple moving average of -53.45% for the last 200 days.
Is It Worth Investing in DBV Technologies ADR (NASDAQ: DBVT) Right Now?
The 36-month beta value for DBVT is also noteworthy at 0.62. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for DBVT is 94.42M, and at present, short sellers hold a 1.41% of that float. The average trading volume of DBVT on November 19, 2024 was 659.06K shares.
DBVT) stock’s latest price update
DBV Technologies ADR (NASDAQ: DBVT)’s stock price has decreased by -13.53 compared to its previous closing price of 0.59. However, the company has seen a -24.44% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-11 that Châtillon, France, November 11, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J200), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per share, from the current ADS Ratio of one (1) ADS to one (1) ordinary share to a new ADS Ratio of one (1) ADS to five (5) ordinary shares (the “ADS Ratio Change”). The Company anticipates that the ADS Ratio Change will be effective on or about November 29, 2024 (the “Effective Date”).
Analysts’ Opinion of DBVT
Goldman gave a rating of “Neutral” to DBVT, setting the target price at $1.50 in the report published on May 10th of the previous year.
DBVT Trading at -28.53% from the 50-Day Moving Average
After a stumble in the market that brought DBVT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.17% of loss for the given period.
Volatility was left at 12.12%, however, over the last 30 days, the volatility rate increased by 10.61%, as shares sank -27.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.62% lower at present.
During the last 5 trading sessions, DBVT fell by -24.44%, which changed the moving average for the period of 200-days by -71.67% in comparison to the 20-day moving average, which settled at $0.7176. In addition, DBV Technologies ADR saw -73.24% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DBVT starting from Mohideen Pharis, who sale 1,785 shares at the price of $0.98 back on Jul 29 ’24. After this action, Mohideen Pharis now owns 79,367 shares of DBV Technologies ADR, valued at $1,749 using the latest closing price.
Mohideen Pharis, the Chief Medical Officer of DBV Technologies ADR, sale 660 shares at $1.36 during a trade that took place back on May 24 ’24, which means that Mohideen Pharis is holding 81,152 shares at $898 based on the most recent closing price.
Stock Fundamentals for DBVT
Current profitability levels for the company are sitting at:
- -7.4 for the present operating margin
- 1.43 for the gross margin
The net margin for DBV Technologies ADR stands at -7.72. The total capital return value is set at -1.36. Equity return is now at value -103.11, with -72.19 for asset returns.
Based on DBV Technologies ADR (DBVT), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -150.23.
Currently, EBITDA for the company is -85.98 million with net debt to EBITDA at 0.38. When we switch over and look at the enterprise to sales, we see a ratio of 0.94. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.22.
Conclusion
In summary, DBV Technologies ADR (DBVT) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
